Back to results
US 2023/0406843 A1Published application
Progranulin Modulators and Methods of Using the Same
AssigneeArkuda Therapeutics
InventorsDuane A. Burnett, James C. Lanter
Life of this patent
Estimating the term…
Abstract
Provided herein are compounds that modulate progranulin and methods of using the compounds in progranulin-associated disorders, such as Frontotemporal lobe dementia (FTLD).
Claims79
A compound, or pharmaceutically acceptable salt thereof, having a structure of Formula (I):
- wherein
- ring A is a 4- to 12-membered heterocycle comprising a ring O or S atom, further comprising 0-3 additional ring heteroatoms selected from O, N, and S;
- R1 is hydrogen, C1-6alkyl, halo, C1-3 haloalkyl, O—C1-3 haloalkyl,C1-3 alkylene-CN, C1-3 alkylene-NRN2, C0-6 alkylene-ORN, C0-6 alkylene- C(O)ORN, C0-6 alkylene-C(O)N(RN)2, or C0-6 alkylene-SOpRN;
- each RN is independently hydrogen or C1-6alkyl, and p is 0-2;
- each R2 is independently halo;
- each R3 is independently hydrogen, halo, C1-6alkyl, C1-6haloalkyl, C0-6alkylene-OH, C1-6alkoxy, C1-6 haloalkoxy, C1-6alkylene-O—C1-6alkyl, C0-6alkylene-NRaRb, S—C1-6alkyl, C2-6alkenyl, C(O)—C1-6haloalkyl, SO2—C1-6 alkyl, S2+(O)—(NRa)—C1-6alkyl, OR4, 5- to 8-membered heteroaryl comprising 1-4 ring N atoms, or 4- to 6-membered heterocycle comprising 1-4 ring heteroatoms selected from O, N, and S with at least 1 ring heteroatom being N, and the heteroaryl or heterocycle is optionally substituted with 1 or 2 substituents independently selected from halo, C1-6alkyl, OH, and C1-6alkoxy, or
- two geminal R3 together with the atom to which they are attached form an oxo group, and
- when ring A comprises a ring N atom, the N is substituted with Ra, and if ring A does not comprise a ring N atom, then at least one R3 is C0-6alkylene-NRaRb;
- Ra and Rb are each independently hydrogen, C1-6alkyl, C1-6haloalkyl, C1-6alkylene-OH, C1-6alkylene-O—C1-6alkyl, C(O)—C1-6alkyl, C(O)—C1-6haloalkyl, S(O)2—C1-6alkyl, S(O)2—C1-6haloalkyl;
- or
- Ra and Rb together with the nitrogen to which they are attached form a 3- to 12-membered monocyclic or bicyclic heterocycle optionally further comprising 1-3 additional ring heteroatoms selected from O, N, and S;
- R4 is C2-6alkenyl, C2-6alkynyl, C0-6alkylene-C3-6cycloalkyl, or C0-6alkylene-C6-10aryl;
- each Rd is independently H or D;
- each Re is independently H, D, halo, OH, methyl, or methoxy, or
- two geminal Re together with the atom to which they are attached form an oxo group or a spiro C3-5cycloalkyl;
- m is 1-4;
- and
- n is 0-2.
15 more elements
The compound or salt of claim 33, wherein R3 is
A compound, or pharmaceutically acceptable salt thereof, having a structure as shown in Table A.
Dependencies are inferred from the claim text.